NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...
A pore smaller than one nanometer reads peptide sequences amino acid by amino acid, pinpointing single-site Alzheimer's ...
A refined base-pair editor limits unintended neighboring DNA edits while maintaining strong correction of disease-causing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results